LivaNova completes enrollment of 500th unipolar patient in RECOVER depression trial

LivaNova PLC

Independent committee advised enrollment to continue from 475 to 500 unipolar patients per protocol.
500th unipolar patient randomized on March 23, 2023; final analysis after 12-month follow-up data.
Trial evaluates Vagus Nerve Stimulation for difficult-to-treat depression; results to be published.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.